HIGHLIGHTS
- who: Prakash Khadka from the School of Pharmacy, University of Otago, Dunedin, New Zealand have published the research work: A review of formulations and preclinical studies of inhaled rifampicin for its clinical translation, in the Journal: (JOURNAL)
- what: Although a high dose of rifampicin is a requirement for the efficient treatment of TB, studies focusing on a high dose of rifampicin are rare in the literature. Despite the studies discussed above, the pharmacokinetics of rifampicin after inhaled administration of higher doses (> 20 mg/kg) remained unknown. The pulmonary drug delivery technique to animals depends on . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.